- Welcome and Introduction
- Assessing Risk and Individualizing Adjuvant Therapy in HR+/HER2- Early Breast Cancer
- Selection and Sequencing of Targeted Therapy for HR+/HER2- Advanced and Metastatic Breast Cancer
- Adverse Event Management and Strategies to Promote Adherence to Oral Targeted Therapies
- Audience Question and Answer Session and Final Thoughts
Date / Time
JW Marriott Chicago
Komal Jhaveri, MD
Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Erica Mayer, MD, MPH
Breast Oncology Center
Dana-Farber Cancer Institute
The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for HR+/HER2- breast cancer.
This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.
Upon completion of this activity, participants should be able to:
- Plan risk-adapted adjuvant treatment strategies for patients with early-stage HR+/HER2- breast cancer based on available evidence and use of risk assessment algorithms, cellular proliferation biomarkers, and multigene assays
- Select individualized treatment for patients with HR+/HER2- metastatic breast cancer based on the available evidence, guidelines, tumor characteristics, patient preferences, and expert guidance
- Apply appropriate strategies to increase medication adherence rates in breast cancer patients to improve outcomes and mitigate medication resistance
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.